SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K Current Report was filed on May 4, 2010, by India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc. in metadata). The report addresses a regulatory compliance issue with the NYSE Amex LLC regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and listing compliance.
Material Changes and Events
- Listing Non-Compliance: On March 31, 2010, the company received notice from the NYSE Amex LLC of non-compliance with Section 704 of the Exchange's Company Guide due to the failure to hold an annual meeting of stockholders during 2009.
- Compliance Plan Submission: The company submitted a plan by the April 30, 2010 deadline, proposing to hold a stockholder meeting on or before September 30, 2010.
- Extension Granted: On April 30, 2010, the Exchange approved the plan, granting an extension to regain compliance by September 30, 2010.
Outlook, Risks, and Management Commentary
Management must provide periodic updates to the Exchange regarding the initiatives in the compliance plan. The Exchange will review progress periodically. A material risk exists that if the company fails to progress as set forth in the plan or fails to regain compliance by September 30, 2010, the Exchange may immediately commence delisting proceedings.
Investor Verification Checklist
- Verify the scheduled date for the upcoming annual meeting of stockholders to ensure it occurs on or before September 30, 2010.
- Monitor future 8-K filings for updates on the company's progress toward compliance.
- Confirm the company's current ticker symbol and listing status on the NYSE Amex, as delisting proceedings could be initiated if the deadline is missed.